The authors conclude that community cancer centers are capable of conducting early-phase trials; infrastructure and collaborations are critical components of success.
Abstract
Purpose:
The National Cancer Institute (NCI) Community Cancer Centers Program (NCCCP) formed an Early-Phase Working Group to facilitate site participation in early-phase (EP) trials. The Working Group conducted a baseline assessment (BA) to describe the sites' EP trial infrastructure and its association with accrual.
Methods:
EP accrual and infrastructure data for the sites were obtained for July 2010-June 2011 and 2010, respectively. Sites with EP accrual rates at or above the median were considered high-accruing sites. Analyses were performed to identify site characteristics associated with higher accrual onto EP trials.
Results:
Twenty-seven of the 30 NCCCP sites participated. The median number of EP trials open per site over the course of July 2010-June 2011 was 19. Median EP accrual per site was 14 patients in 1 year. Approximately half of the EP trials were Cooperative Group; most were phase II. Except for having a higher number of EP trials open (P = .04), high-accruing sites (n = 14) did not differ significantly from low-accruing sites (n = 13) in terms of any single site characteristic. High-accruing sites did have shorter institutional review board (IRB) turnaround time by 20 days, and were almost three times as likely to be a lead Community Clinical Oncology Program site (small sample size may have prevented statistical significance). Most sites had at least basic EP trial infrastructure.
Conclusion:
Community cancer centers are capable of conducting EP trials. Infrastructure and collaborations are critical components of success. This assessment provides useful information for implementing EP trials in the community.
Introduction
The National Cancer Institute (NCI) Community Cancer Centers Program (NCCCP) is a network of community cancer centers that strives to expand cancer research capacity and deliver advanced care in the community.1–2 The program was launched in 2007 as a 3-year pilot forming a public-private partnership with 16 community hospitals. In 2010, American Recovery and Reinvestment Act (ARRA) funding enabled the NCI to expand the network to a total of 30 sites.
One of the goals of the NCCCP is to increase capacity for community cancer centers to participate in early-phase (EP) clinical trials (phases I-II) so that patients with cancer do not have to routinely seek opportunities for trial participation outside of their communities. The benefits of achieving such a goal include the ability to offer more treatment options closer to home as well as to help contribute accrual to important trials, as the majority (∼85%) of patients with cancer are treated in community settings.3 Indeed, approximately 65% of patients entered onto NCI Cooperative Group trials are enrolled from community-based practices, such as the NCI Community Clinical Oncology Program (CCOP) and academic medical center affiliates.4
Sites did have to satisfy certain baseline performance requirements for entering the NCCCP. For example, sites had to have accrued at least 25 patients per year for the last 3 years to any phase of treatment, prevention, or cancer control trial. NCCCP sites ranged in their level of experience in EP trials, from sites just embarking on building their EP trial programs, to sites already experienced in EP trials. Two NCCCP projects, supported by American Recovery and Reinvestment Act funding, were specifically geared towards increasing NCCCP involvement in EP clinical trials, one via NCCCP site infrastructure development, and the other via NCCCP site collaborations with NCI-designated cancer centers.
In 2010, the NCCCP, through its Clinical Trials Subcommittee, formed an Early-Phase Working Group (EPWG) to collaborate on expanding efforts to implement EP clinical trials among its member sites. Membership was open to any interested NCCCP site. A range of clinical trialists from a majority of NCCCP sites participated in the EPWG, including site investigators, participating physicians, research nurses, clinical research associates/coordinators, and NCI clinical trial advisors.
Major objectives of the EPWG were to assess the NCCCP sites' EP clinical trials infrastructure by conducting a baseline assessment (BA) to determine how that infrastructure was associated with EP accrual, and to exchange best practices to help expand sites' ability to offer and/or better refer to EP trials. This article describes the results from the assessment.
Methods
Information about each NCCCP site's EP trial infrastructure and performance formed the BA and was gathered from a variety of sources, including site progress reports, existing NCI trials databases, and a questionnaire developed by the EPWG. The time period covered was primarily 2010 for the infrastructure assessment and July 2010-June 2011 for EP trial performance. To determine which data items to include in the BA, literature was reviewed and expert opinion sought, including criteria used by seasoned academic EP investigators to evaluate site capability for participating in multicenter EP trials.5–11
Analyses were performed to identify site characteristics associated with higher accrual into EP trials. EP accrual rate per site was calculated as EP accrual per 1,000 new analytic cases seen in a year. High-accruing sites were defined as sites with an EP accrual rate at or above the median. Mann-Whitney and Fisher's exact tests were used to compare continuous and categorical variables, respectively, among subgroups.
Results
Twenty-seven of the 30 sites completed the BA. These sites cared for approximately 56,000 new patients annually and had a substantial population of rural and racial/ethnic minority patients (Table 1). Three sites did not respond to the BA, providing the following reasons: not yet participating in EP trials (two sites) and lack of time (one site).
Table 1.
Site Characteristics: National Cancer Institute Community Cancer Centers Program*
| Site Characteristics (N = 27) | Median | Range |
|---|---|---|
| Annual analytic cases | 1,871 | 526-3,585 |
| Population | ||
| Urban | 71% | 0-100 |
| Rural | 29% | 0-100 |
| Race/ethnicity | ||
| White | 81% | 25-97 |
| African American | 8% | <1-52 |
| Asian | 2% | 0-54 |
| Hawaiian/Pacific Islander | 0% | 0-18 |
| American Indian/Alaska Native | 0% | 0-2 |
| Hispanic/Latino | 5% | 0-52 |
| Data management | ||
| Electronic medical record | 70% | |
| Clinical data management systems | 81% | |
| Electronic data capture | 100% | |
| Infrastructure, percentage of sites | ||
| Biopsy: additional biopsy capability | 89% | |
| Clinical research unit (for any type of trial, including cancer) | 19% | |
| Freezer: −80°C to −20°C freezer for specimens | 89% | |
| Freezer: standard freezer for specimens | 100% | |
| PK/PD capability | 85% | |
| Pharmacy with experience with investigational agents | 100% | |
| Radiation therapy on site | 96% | |
| Refrigerator for specimens | 100% | |
| Specific inpatient accommodations for clinical trials (eg, dedicated beds) | 33% | |
| Specimens: capacity to collect, handle, and send | 100% | |
| Staffing† | ||
| Regulatory | ||
| Institutional review board turnaround time, days | 45 | 7-71 |
| Institutional biosafety committee utilized, percentage of sites | 30% | |
| Trial sponsors, percentage of sites | ||
| Sites with Cooperative Group EP trials open | 93% | |
| Sites with industry EP trials open | 81% | |
| Sites with NCI-designated cancer center EP trials open | 48% | |
| Sites with local EP trials open | 22% | |
| Collaborations with NCI programs, percentage of sites | ||
| Cooperative Group membership | 100% | |
| Use of NCI Cancer Trials Support Unit for EP participation | 70% | |
| NCI CCOP | 48% | |
| Funding source distribution‡ | ||
| Cancer center | 0% | 0%–50% |
| Federal | 41% | 0%–82% |
| Hospital | 0% | 0%–99% |
| Industry | 26% | 0%–65% |
| Philanthropy | 0% | 0%–80% |
| Trial composition per site | ||
| No. of EP trials open per site during July 2010-June 2011 | 19 | 1-66§ |
| Proportion of sponsor's trials per site | ||
| Cooperative Groups | 76% | 0%–100% |
| Industry | 13% | 0%–78% |
| Local | 0% | 0%–17% |
| NCI-designated cancer centers | 1% | 0%–43% |
| Other | 0% | 0%–12% |
| Accrual to EP trials per site in 1 year | ||
| No. accrued | 14 | 0-67 |
| Rate (No. accrued/1,000 new analytic cases) | 7 | 0-67 |
Abbreviations: CCOP, Community Clinical Oncology Program; CTEP, Cancer Therapy Evaluation Program; EP, early-phase; NCI, National Cancer Institute; PK/PD, pharmacokinetic/pharmacodynamic.
For 27 responding sites.
Please see Results and Discussion sections.
Three responding sites did not answer this question.
Number of open EP trials at a site may also reflect EP trials open at a lead site (eg, a lead CCOP site) with which that National Cancer Institute Community Cancer Centers Program site is affiliated.
Infrastructure
Infrastructure characteristics of NCCCP sites are summarized in Table 1. Almost all responding sites reported having at least some basic infrastructure elements for EP trials, such as the capacity for handling biospecimens and pharmacokinetic/pharmacodynamic studies, as well as a pharmacy experienced in the handling of investigational agents. Twenty-four of the 27 sites responded that they had the capability to perform an additional biopsy for trials requiring them, with two of these noting they had a limited ability to do so.
Staff roles identified across the sites included those of investigator, physician assistant/nurse practitioner, research nurse, clinical research associate (CRA)/coordinator (CRC), data manager, biospecimen technician, oncology research pharmacist, and regulatory coordinator. Most sites (89%) had at least one person who performed CRA/CRC and/or research nurse duties for EP trials at least part-time. A minority of sites reported use of nurse or patient navigators and quality assurance personnel specifically for EP trials.
Sites found it challenging to quantify staffing focused only on EP trials in granular ways (eg, “data management”), as staff performed multiple, overlapping roles across different types and phases of studies as well as duties related to standard care. Many individual personnel fulfilled more than one role, such as CRCs also performing the roles of data manager, regulatory coordinator, and/or research nurse, and research nurses also being responsible for regulatory coordination and/or quality assurance, to name a few examples.
Twenty sites provided information about the funding sources for their EP trials. The largest funding source was NCI and other federal support, followed by industry. Hospital, philanthropic, and cancer center funding accounted for much smaller percentages of funding. Across sites, these last three categories, which represent “self-funding” by the sponsoring institution, comprised approximately one third of total funding.
Regulatory Committees
Most (n = 23; 85%) sites used a local institutional review board (IRB). More than half of these sites (n = 12) also used at least one external IRB. Four sites used external IRBs solely, either a non-NCI central or regional IRB, or another institution's IRB. Local IRB protocol turnaround time (median, 45 days) was generally slower compared to both non-NCI central/regional IRB (median of 21 days) and NCI central IRB (median, 7 days; used by three sites), but faster than external institution IRB (median, 70 days). Eight sites (30%) used an institutional biosafety committee.
External Collaborations
All sites reported membership in NCI's Clinical Trials Cooperative Group Program (Cooperative Groups; Table 1). A majority (70%) participated in EP trials through the Cancer Trials Support Unit (CTSU), and half participated in EP trials via the NCI CCOPs. Cooperative Group, NCI-designated cancer center, and industry-sponsored EP trials were available in 93%, 48%, and 81% of sites, respectively.
EP Trial Features
Across sites, there were 291 unique EP trials open over the course of the BA period, with a median of 19 trials per site (Table 1). (“Unique” trials are counted only once, regardless of how many times the same trial is opened by different sites.) Number of open EP trials at a site may have also reflected EP trials open at a lead site (eg, a lead CCOP site) with which that NCCCP site was affiliated. Eighty-two percent of these trials were phase II, 11% phase I/II, and 7% phase I. Phase I, I/II, and II trials were open at nine, 19, and 26 of the 27 sites, respectively.
Additional EP trial features are shown in Table 2. Almost half (128) of the unique trials were phase II Cooperative Group trials. Most NCCCP EP accrual was to Cooperative Group (43% of a total of 433 EP accrual) and industry (30%) trials, with a fair portion (17%) also going to NCI-designated cancer center EP trials. The top three cancers studied were hematologic, lung, and gastrointestinal. The 10 EP trials with the most NCCCP accrual are shown in Appendix Table A1 (online only).
Table 2.
Features of 291 Unique EP Trials Open Across 27 NCCCP Sites Over the Course of July 2010-June 2011
| Trial Features | No. of Trials | % |
|---|---|---|
| Phase | ||
| I | 19 | 7% |
| I/II | 33 | 11% |
| II | 239 | 82% |
| Total unique EP trials | 291* | 100% |
| Sources | ||
| Cooperative Groups | 141 | 48% |
| Industry | 98 | 34% |
| Local | 14 | 5% |
| NCI-designated cancer centers | 31 | 11% |
| Other | 7 | 2% |
| Disease site | ||
| Hematologic | 64 | 22% |
| Lung | 50 | 17% |
| Gastrointestinal | 43 | 15% |
| Breast | 31 | 11% |
| Gynecologic | 30 | 10% |
| Genitourinary | 23 | 8% |
| Brain | 13 | 4% |
| Head and neck | 10 | 3% |
| Melanoma | 8 | 3% |
| Other | 19 | 7% |
| Lead organization (top 10, including ties) | ||
| Southwest Oncology Group | 28 | 10% |
| Eastern Cooperative Oncology Group | 24 | 8% |
| North Central Cancer Treatment Group | 21 | 7% |
| Sarah Cannon Research Institute | 20 | 7% |
| Gynecologic Oncology Group | 20 | 7% |
| Radiation Therapy Oncology Group | 19 | 7% |
| Cancer and Leukemia Group B | 18 | 6% |
| Eli Lilly | 8 | 3% |
| University of Wisconsin | 7 | 2% |
| Children's Oncology Group | 6 | 2% |
| Providence Health & Services | 6 | 2% |
| American College of Surgeons Oncology Group | 5 | 2% |
| University of Nebraska | 5 | 2% |
Abbreviations: CCOP, Community Clinical Oncology Program; EP, early-phase; NCCCP, National Cancer Institute Community Cancer Centers Program; NCI, National Cancer Institute.
Number of open EP trials at a site may also reflect EP trials open at a lead site (eg, a lead CCOP site) with which that NCCCP site is affiliated.
EP Accrual Rate and Association With Site Characteristics
The median EP accrual was 14 patients per site for the year. The EP accrual rate per site was seven accruals per 1,000 new analytic cases (Table 1). No statistically significant differences were found between high-accruing sites and low-accruing sites in terms of any single site characteristic, such as the number of annual analytic cases, collaborations, funding sources, IRB review time, and staffing. The only exception was that high-accruing sites had three times as many EP trials open compared with low-accruing sites (39 v 13; P = .04; Table 3).
Table 3.
Comparison of High- Versus Low-Accruing Sites
| Site Characteristic | High-Accruing Sites (n = 14) |
Low-Accruing Sites (n = 13) |
P | ||
|---|---|---|---|---|---|
| Median | Range | Median | Range | ||
| Annual new analytic case | 1,647 | 526-3,585 | 2,400 | 1,277-3,354 | .47 |
| Collaborations | |||||
| NCI CCOP membership | |||||
| Primary only | 43% | 15% | .21 | ||
| Primary or affiliate | 57% | 38% | .45 | ||
| No. of Cooperative Groups of which site is member | 5 | 1-8 | 3 | 0-6 | .15 |
| NCI CTSU participation | 79% | 62% | .42 | ||
| Funding source (distribution)* | |||||
| Cancer center | 0% | 0%-20% | 10% | 0%-50% | .11 |
| Federal | 46% | 0%-82% | 40% | 0%-75% | .51 |
| Hospital | 0% | 0%-99% | 0% | 0%-75% | .82 |
| Industry | 23% | 0%-65% | 31% | 10%-50% | .49 |
| Philanthropy | 0% | 0%-80% | 0% | 0%-5% | .85 |
| Institutional review board turnaround time, days | 32 | 7-71 | 52 | 10-60 | .18 |
| No. of EP trials open (all sources)† | 39 | 6-66 | 13 | 0-53 | .04 |
Abbreviations: CCOP, Community Clinical Oncology Program; CTSU, Cancer Trials Support Unit; EP, early-phase; NCCCP, National Cancer Institute Community Cancer Centers Program; NCI, National Cancer Institute.
Data from 20 sites.
Over the course of July 2010-June 2011. Number of open EP trials at a site may also reflect EP trials open at a lead site (eg, a lead CCOP site) with which that NCCCP site is affiliated.
Although not statistically significant (perhaps due to small sample size), sites that were high-accruing were almost three times as likely to be a lead CCOP site when compared with low-accruing sites. Likewise, we found a non–statistically significant though sizable difference in IRB turnaround times between low- and high-accruing sites: turnaround time was shorter for high-accruing sites by 20 days.
Discussion
A major pillar of performance for the NCCCP sites is to increase awareness of and participation in EP clinical trials at community cancer centers. The infrastructure for phase II trials is within reach of most community cancer centers that are experienced in clinical trials. This fact is of growing importance as more targeted agents are being studied using phase II (particularly randomized) designs.12–13 Although the infrastructure needed for phase I studies is initially more daunting for community cancer centers, some sites within the NCCCP have made progress in implementing phase I trials.14
During our EPWG monthly conference calls, we learned that many sites were not initially aware that the CTSU has phase II trials available for cross–Cooperative Group participation, with the number of EP trials available through the CTSU gradually increasing over the years from the first EP trial in 2002, to 25 in 2012.15 Participation in EP Cooperative Group trials offered on the CTSU is one way community cancer centers can increase their access to EP trials. Collaborations with NCI-designated cancer centers and industry offer additional routes, often after sites have demonstrated successful accrual to Cooperative Group phase II trials. Indeed, our assessment found that sites were partnering with Cooperative Groups, NCI-designated cancer centers, and industry to participate in EP trials. In addition, a few sites conducted their own EP trials.
High-accruing sites were almost three times as likely to be a CCOP lead site, compared with low-accruing sites. Although this difference was not statistically significant, perhaps as a result of small sample size, it is still sizable enough to be potentially practically significant. It could be postulated that the CCOP hospitals participating in the NCCCP had the advantage of using their well-established clinical trial infrastructure to expand into more EP trial activity. Minasian et al have discussed the importance of such infrastructure, reporting on 25 years of successful clinical research in the CCOP community networks.16 Others have reported an association between CCOP affiliation and higher accrual and/or trial participation.17–18
Interestingly, volume of new cancer cases per site was not associated with EP trial accrual. This finding seems to point to institutional commitment to research. Petrelli et al19 report that 30% of oncologists are responsible for 70% of accrual to NCI trials. The Institute of Medicine similarly reports that only a small percentage of physicians enroll the majority of patients participating in Cooperative Group trials.4
Although 85% or more of sites had basic infrastructure for trials, it appears that the infrastructural barriers faced by sites seeking to implement EP trials go beyond the basics of having freezers, refrigerators, a pharmacy with experience in investigational agents, and specimen-handling capability. A survey of oncologists by Meropol et al20found that lack of staffing was the most significant practical barrier to participating in clinical trials. The NCCCP sites reported that staff at the sites filled a range of roles, with several instances of one person fulfilling multiple roles. This highlights the importance of having sufficient, trained staff, with clearly delineated roles, assigned to research.
If only a small number of physicians at sites do the majority of accruing, then they need highly trained CRAs/CRCs or other dedicated clinical research staff to be able to maintain high levels of research activity. A recent Journal of Oncology Practice series underscores this point.21 The series describes the need for the oncology community to “create a research-centered culture.” Such a culture would require commitment from hospital leadership, oncologists, clinicians, and research staff to foster collaborations essential to accessing clinical trials that would allow patients to receive their cancer treatments closer to home and their support networks. It may also mean that sites should examine their IRB turnaround times, which our assessment found to be shorter by 20 days for high-accruing sites.
Our finding that a higher number of open treatment trials was associated with higher accrual is congruent with the findings of Weiner et al,22 who found number of trials (with at least one accrual) to be a contributing factor to higher accrual in the community setting, when combined with a high number of either new cancer cases or affiliated hospitals or practices.
Limitations to our assessment include the fact that all of the BA data on infrastructure were self-reported; only 1 year of accrual restricted to EP trials was analyzed; the sample size was relatively small; and information on the site's entire clinical trials portfolio, which could affect a site's ability to open EP trials, was not available. Our assessment represents a baseline profile of the NCCCP sites' infrastructure; further follow-up is needed to evaluate site progress and any associations among site characteristics and accrual that could possibly emerge over a longer time frame.
From a methodological perspective, we found that clinical trial staffing may best be examined in terms of total number of staff and in context of the overall portfolio of a site's studies (eg, EP, phase III, cancer control studies, and prevention trials) as opposed to trying to pinpoint full-time equivalents of one particular role (eg, data management) specifically devoted to EP trials. The “fuzzy-set analysis” approach of Weiner et al,22 in which “recipes” of infrastructural components were examined in combination, as opposed to one particular element in isolation, may be a more appropriate method to describe the complexities of research staffing—or infrastructure in general—at sites.
This assessment does support the published literature documenting community commitment and capability to participate in research to advance cancer care.4,16,22 In addition to bringing more research to the community at an earlier stage, community site participation in EP trials could also address the increasing need for clinical trials to screen ever more patients as newly identified cancer molecular subtypes further refine and narrow trial eligibility.4,14 Inherent to this focus on molecular eligibility will be the need for more community sites to collect high-quality biospecimens with annotated data, such as tissue biopsies taken during the trial screening process and possibly other time points when integral to a study design.
In conclusion, community sites represent a key component in our nation's clinical trials system,4 not only as they participate in more traditional later-phase trials, but also for their potential contributions to EP trials. Community sites can serve as a resource for aiding accrual to EP trials. Moreover, as the science evolves, EP trials can provide a vehicle for bringing promising new anticancer agents to patients more rapidly. To these ends, community sites should be engaged in EP trials.
Acknowledgment
Supported by National Cancer Institute Contract No. HHSN261200800001E. Previously presented as an abstract at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago, IL. The background of the NCCCP, the planned evaluation of its overall pilot, and its collaboration in ASCO's Quality Oncology Practice Initiative have been previously published.1-2
Appendix
Table A1.
EP Trials With the Highest NCCCP Accrual (July 2010-June 2011)
| Trial ID | Phase | Cancer | Stage | Intervention | Lead Organization | Sponsor | Accrual from NCCCP Sites* |
|---|---|---|---|---|---|---|---|
| NCT01106898 | II | Breast | I-II | Adjuvant cyclophosphamide, paclitaxel ± trastuzumab | University of Nebraska | NCI-designated cancer center | 23 |
| NCT00861705 | II | Breast | II-III, ER/PR poor, HER2 negative | Neoadjuvant addition of carboplatin ± bevacizumab to weekly paclitaxel followed by dose-dense doxorubicin/cyclophosphamide | CALGB | NCI | 17 |
| NCT00828841 | II | Lung non–small-cell | IIIb-IV/relapsed | Cetuximab + platinum-based chemotherapy | Accelerated Community Oncology Research Network | Industry | 16 |
| NCT00881361 | II | Breast | II-III | Sentinel node surgery and axillary node dissection following neoadjuvant chemotherapy | ACOSOG | NCI | 12 |
| NCT00614822 | II | Lung non–small-cell | IIIb-IV | Carboplatin, bevacizumab and pemetrexed | Christiana Care Health Services/ Eli Lilly | Industry | 11 |
| NCT01295723 | I | Breast | I | Intraoperative boost radiotherapy with electrons followed by hypofractionated whole-breast radiation | St. Joseph Hospital of Orange | Institutional | 11 |
| NCT00986674 | II | Lung non–small-cell | IIIb-IV | Carboplatin and paclitaxel in combination with cetuximab, insulin-like growth factor 1 receptor antibody IMC-A12 or both | ECOG | NCI | 10 |
| NCT00928174 | I/II | Prostate | Androgen insensitive | Measurement of anti-androgen response with 18F-choline PET/CT in androgen insensitive prostate cancer | Queen's Medical Centre | Institutional/NCI | 10 |
| NCT00887159 | II | Lung small-cell | Extensive | Cisplatin and etoposide + hedgehog inhibitor GDC-0449 or insulin-like growth factor 1 receptor antibody IMC-A12 | ECOG | NCI | 9 |
| NCT00603863 | I/II | Pancreatic | III-IV | Fractionated 90Y-labeled anti-mucin humanized antibody (90Y-hPAM4) + gemcitabine | Immunomedics | Industry | 9 |
Abbreviations: ACOSOG, American College of Surgeons Oncology Group; CALGB, Cancer and Leukemia Group B; ECOG, Eastern Cooperative Oncology Group; EP, early-phase; ER, estrogen receptor; HER, human epidermal growth factor receptor; NCCCP, National Cancer Institute Community Cancer Centers Program; NCI, National Cancer Institute; NCT, ClinicalTrials.gov identifier; PR, progesterone receptor.
Accrual shown is from NCCCP sites participating in the BA.
Authors' Disclosures of Potential Conflicts of Interest
Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.
Employment or Leadership Position: None Consultant or Advisory Role: Michael A. Thompson, Teva (C), CytRx Corporation (C) Stock Ownership: None Honoraria: None Research Funding: Michael A. Thompson, Novartis Expert Testimony: None Other Remuneration: None
Author Contributions
Conception and design: Howard A. Zaren, Suresh Nair, Ronald S. Go, Rebecca A. Enos, Michael A. Thompson, Donna M. Bryant, Maria M. Gonzalez, Kathy Wilkinson, Andrea M. Denicoff
Administrative support: Rebecca A. Enos, Andrea M. Denicoff
Provision of study materials or patients: Howard A. Zaren, Suresh Nair, Ronald S. Go, Keith S. Lanier, Michael A. Thompson, Deborah L. Fleming, John C. Leighton, Thomas E. Gribbin, Donna M. Bryant, Jennifer C. Corpening, Kimberly A. Csapo, Christie Ellison, Maria M. Gonzalez, Jodi L. Harr, Kathy Wilkinson
Collection and assembly of data: Howard A. Zaren, Suresh Nair, Ronald S. Go, Rebecca A. Enos, Jinxiu Zhao, Deborah L. Fleming, Thomas E. Gribbin, Donna M. Bryant, Angela Carrigan, Kimberly A. Csapo, Eileen P. Dimond, Christie Ellison, Maria M. Gonzalez, Andrea M. Denicoff
Data analysis and interpretation: Howard A. Zaren, Suresh Nair, Ronald S. Go, Rebecca A. Enos, Michael A. Thompson, Jinxiu Zhao, John C. Leighton, Donna M. Bryant, Eileen P. Dimond, Andrea M. Denicoff
Manuscript writing: Howard A. Zaren, Suresh Nair, Ronald S. Go, Rebecca A. Enos, Keith S. Lanier, Michael A. Thompson, Deborah L. Fleming, Donna M. Bryant, Jennifer C. Corpening, Maria M. Gonzalez, Kathy Wilkinson, Andrea M. Denicoff
Final approval of manuscript: All authors
References
- 1.Clauser SB, Johnson MR, O'Brien DM, et al. Improving clinical research and cancer care delivery in community settings: Evaluating the NCI Community Cancer Centers Program. Implement Sci. 2009;4:63. doi: 10.1186/1748-5908-4-63. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Siegel RD, Clauser SB, Lynn JM. National collaborative to improve oncology practice: The National Cancer Institute Community Cancer Centers Program Quality Oncology Practice Initiative experience. J Oncol Pract. 2009;5:276–281. doi: 10.1200/JOP.091050. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.National Cancer Institute. Frequently Asked Questions: NCI Community Cancer Centers Program Pilot: 2007-2010. http://ncccp.cancer.gov/Media/FactSheet.htm.
- 4.Institute of Medicine. Washington, DC: National Academies Press; 2010. A national cancer clinical trials system for the 21st century: Reinvigorating the NCI Cooperative Group Program. [PubMed] [Google Scholar]
- 5.Abdel-Rahman SM, Reed MD, Wells TG, et al. Considerations in the rational design and conduct of phase I/II pediatric clinical trials: Avoiding the problems and pitfalls. Clin Pharmacol Ther. 2007;81:483–494. doi: 10.1038/sj.clpt.6100134. [DOI] [PubMed] [Google Scholar]
- 6.Craft BS, Kurzrock R, Lei X, et al. The changing face of phase 1 cancer clinical trials: New challenges in study requirements. Cancer. 2009;115:1592–1597. doi: 10.1002/cncr.24171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Gwede CK, Johnson D, Trotti A. Measuring the workload of clinical research coordinators: Part 1— Tools to study workload issues. Appl Clin Trials. 2000;9:40–47. [Google Scholar]
- 8.Karavasilis V, Digue L, Arkenau T, et al. Identification of factors limiting patient recruitment into phase I trials: A study from the Royal Marsden Hospital. Eur J Cancer. 2008;44:978–982. doi: 10.1016/j.ejca.2008.02.040. [DOI] [PubMed] [Google Scholar]
- 9.LoRusso PM, Boerner SA, Seymour L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clin Cancer Res. 2010;16:1710–1718. doi: 10.1158/1078-0432.CCR-09-1993. [DOI] [PubMed] [Google Scholar]
- 10.Roche K, Paul N, Smuck B, et al. Factors affecting workload of cancer clinical trials: Results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2002;20:545–556. doi: 10.1200/JCO.2002.20.2.545. [DOI] [PubMed] [Google Scholar]
- 11.Zon R, Meropol NJ, Catalano RB, et al. American Society of Clinical Oncology statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol. 2008;26:2562–2567. doi: 10.1200/JCO.2007.15.6398. [DOI] [PubMed] [Google Scholar]
- 12.Rubinstein L, Crowley J, Ivy P, et al. Randomized phase II designs. Clin Cancer Res. 2009;15:1883–1890. doi: 10.1158/1078-0432.CCR-08-2031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Schilsky RL. Accrual to cancer clinical trials in the era of molecular medicine. Sci Transl Med. 2011;3:75cm9. doi: 10.1126/scitranslmed.3001712. [DOI] [PubMed] [Google Scholar]
- 14.Wilkinson K. Cutting edge yet close to home: Cancer research in the community. ONS Connect. 2008. Dec, http://www.thefreelibrary.com/Cutting+edge+yet+close+to+home%3A+cancer+research+in+the+community.-a0193247606. [PubMed]
- 15.Cancer Trials Support Unit. CTSU Protocols and Accrual Report. https://www.ctsu.org/
- 16.Minasian LM, Carpenter WR, Weiner BJ, et al. Translating research into evidence-based practice: The National Cancer Institute Community Clinical Oncology Program. Cancer. 2010;116:4440–4449. doi: 10.1002/cncr.25248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Klabunde CN, Keating NL, Potosky AL, et al. A population-based assessment of specialty physician involvement in cancer clinical trials. J Natl Cancer Inst. 2011;103:384–397. doi: 10.1093/jnci/djq549. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Carpenter WR, Tyree S, Wu Y, et al. A surveillance system for monitoring, public reporting, and improving minority access to cancer clinical trials. Clin Trials. 2012;9:426–435. doi: 10.1177/1740774512449531. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Petrelli NJ, Grubbs S, Price K. Clinical trial investigator status: You need to earn it. J Clin Oncol. 2008;26:2440–2441. doi: 10.1200/JCO.2008.16.5050. [DOI] [PubMed] [Google Scholar]
- 20.Meropol NJ, Buzaglo JS, Millard J, et al. Barriers to clinical trial participation as perceived by oncologists and patients. J Natl Compr Canc Netw. 2007;5:655–664. doi: 10.6004/jnccn.2007.0067. [DOI] [PubMed] [Google Scholar]
- 21.Enhancing oncologist participation in research. J Oncol Pract. 2009;5:309–311. doi: 10.1200/JOP.091042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Weiner BJ, Jacobs SR, Minasian LM, et al. Organizational designs for achieving high treatment trial enrollment: A fuzzy-set analysis of the Community Clinical Oncology Program. J Oncol Pract. 2012;8:287–291. doi: 10.1200/JOP.2011.000507. [DOI] [PMC free article] [PubMed] [Google Scholar]